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Original Article
Faecal haemoglobin can define risk of colorectal
neoplasia at surveillance colonoscopy in patients
at increased risk of colorectal cancer.
Jayne Digby1, Shirley Cleary2, Lynne Gray3, Pooja Datt4, David R Goudie5,
Robert J C Steele1, Judith A Strachan6, Adam Humphries4,
Callum G Fraser1 and Craig Mowat2
Abstract
Background: Quantitative faecal immunochemical tests measure faecal haemoglobin concentration (f-Hb), which increases
in the presence of colorectal neoplasia.
Objective: We examined the diagnostic accuracy of faecal immunochemical test (FIT)in patients at increased risk of colo-
rectal cancer (CRC) attending for surveillance colonoscopy as per national guidelines.
Methods: A total of 1103 consecutive patients were prospectively invited to complete a FIT before their scheduled colonos-
copy in two university hospitals in 2014– 2016. F-Hb was analysed on an OC-Sensor io automated analyser (Eiken Chemical
Co., Ltd, Tokyo, Japan) with a limit of detection of 2 mg Hb/g faeces. The diagnostic accuracy of f-Hb for CRC and higher-risk
adenoma was examined.
Results: A total of 643 patients returned a faecal test. After excluding 4 patients with known inflammatory bowel disease,
639 (57.9%) remained in the study: age range: 25–90 years (median: 64 years, interquartile range (IQR): 55–71): 54.6%
male. Of 593 patients who also completed colonoscopy, 41 (6.9%) had advanced neoplasia (4 CRC, 37 higher-risk adenoma).
Of the 238 patients (40.1%) who had detectable f-Hb, 31 (13.0%) had advanced neoplasia (2 CRC, 29 higher-risk adenoma)
compared with 10 (2.8%) in those with undetectable f-Hb (2 CRC, 8 higher-risk adenoma). Detectable f-Hb gave negative
predictive values of 99.4% for CRC and 97.2% for CRC plus higher-risk adenoma.
Conclusion: In patients at increased risk of CRC under colonoscopy surveillance, a test measuring faecal haemoglobin can
provide an objective estimate of the risk of advanced neoplasia, and could enable tailored scheduling of colonoscopy.
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Key Summary
The established knowledge on this subject
• Quantification of faecal haemoglobin concentration (f-Hb) using a Faecal Immunochemical Test (FIT) is
advocated for population bowel screening and as a ‘rule-out’ test within the assessment of new bowel
symptoms presenting to family doctors.
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• A variety of f-Hb have been selected as the cut-off for a ‘positive’ test in diagnostic accuracy studies
published to date.
• Few studies have examined the role of FIT in patients under regular surveillance colonoscopy.
The significant and new findings of this study
• We describe using FIT at the limit of detection (LoD), prior to scheduled surveillance colonoscopy in a
cohort of patients at increased risk of colorectal cancer (CRC).
• With a positive FIT, prevalence of advanced neoplasia was doubled, and with a negative FIT it was reduced
by 60%.
• FIT provides objective evidence of the risk of advanced neoplasia at pending surveillance colonoscopy and
could inform patient-centred colonoscopy scheduling.
Introduction
Early diagnosis of colorectal cancer (CRC) is associat-
ed with improved outcomes,1 and removal of colorectal
adenoma can prevent the subsequent development of
CRC.2 Unfortunately, because any symptoms associat-
ed with CRC are extremely non-specific and, alone,
show poor diagnostic performance,3,4 and because ade-
nomas are generally asymptomatic, individuals who are
at moderate or high risk of developing CRC are rec-
ommended to undergo regular surveillance colonosco-
py. The British Society of Gastroenterology (BSG)
guidelines for Colorectal Cancer Screening and
Surveillance provide the benchmark for practice in
the United Kingdom (UK).5 Individuals are recom-
mended to undergo colonoscopy at specified intervals
according to their individual risk profile. However, pre-
cise surveillance intervals have, to date, been defined
solely by expert opinion. Furthermore, the yield of
pathology at surveillance colonoscopy is low: for exam-
ple, only a 1.8% incidence of CRC in almost 12,000
patients in one study.6 Surveillance colonoscopy is
viewed as the gold standard investigation, but it has a
miss rate of 11% for advanced adenoma, and up to
26% for all adenoma,7,8 is associated with an interval
cancer rate of 0.6% in patients under surveillance,9 and
carries a small but significant risk of complication such
as perforation of the bowel. A better means of surveil-
lance that can triage individuals for colonoscopy at the
appropriate time is urgently required.
Faecal immunochemical tests for haemoglobin
(FIT) measure faecal haemoglobin concentrations
(f-Hb), which are correlated directly with the severity
of any underlying neoplastic colorectal lesions.10 These
are widely used in CRC screening and are now advo-
cated for use in primary care, along with clinical and
laboratory data, as a ‘rule-out’ test in the assessment of
patients presenting with new bowel symptoms and thus
avoid unnecessary colonoscopy.11–15 FIT has been
advocated for the screening of first-degree relatives of
CRC patients,16 and has shown equivalence to colonos-
copy in familial CRC screening.17A number of studies
have examined the utility of FIT within patients under
colonoscopy surveillance, reporting on qualitative and
quantitative assays and suggesting high specificity and
negative predictive values for CRC at low f-Hb cut-
offs.18–21 More recently, a study reported less favour-
able results in patient under adenoma surveillance, but
this used a higher f-Hb cut-off of 40 mg Hb/g faeces.22
There is much current interest in using very low f-Hb
in several clinical settings, since the lower the cut-off,
the more neoplasia will be detected. Analytical perfor-
mance at low f-Hb is defined by the detectability char-
acteristics. These can be described as the limit of
detection (LoD), below which f-Hb is undetectable,
and above which f-Hb is detected; the limit of quanti-
tation (LoQ), above which the f-Hb is quantifiable in
numerical terms; and the working range, which is ana-
lyser dependent and determines the f-Hb that is
reported in practice.23 We aimed to determine the diag-
nostic accuracy of a quantitative FIT at low f-Hb for
advanced neoplasia (CRC plus higher-risk adenoma
(HRA)) at the time of scheduled colonoscopy in indi-
viduals at increased risk of CRC and engaged in a sur-
veillance programme, whether it was feasible and
acceptable to patients, and whether it could be used
to tailor surveillance colonoscopy for individual
patients.
Methods
This prospective study was conducted following the
Standards for Reporting of Diagnostic Accuracy
Studies (STARD) guidelines.24 Consecutive patients
at risk of CRC, as defined by the BSG guidelines for
Colorectal Cancer Screening and Surveillance (2010
edition),5 and enrolled in colonoscopy surveillance at
Ninewells Hospital and Medical School, Dundee from
1 June 2014, for a period of 15 months, and at St
Marks Hospital, London from 1 June 2016, for a
period of 3 months, were eligible. Patients with inflam-
matory bowel disease (IBD) were excluded. Data col-
lection concluded on 30 September 2016.
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Individuals were identified from endoscopy surveil-
lance registers and were contacted in date order as their
appointment time approached by a nurse specialist who
booked a surveillance colonoscopy, provided the
patient still fulfilled the surveillance criteria described
by the BSG guidelines.5 The nurse invited each patient
to submit a single sample of faeces for FIT analysis
prior to colonoscopy. Sample collection for FIT was
completed before bowel preparation started. A FIT
specimen collection device (OC-Sensor, Eiken
Chemical Co., Ltd, Tokyo, Japan) and a pictorial
patient information sheet were sent to the patient’s
home. Samples were returned to Blood Sciences,
NHS (National Health Service) Tayside, and this
implied consent to take part in the study. Analysis
was performed on an OC-Sensor io automated analyser
(Eiken). That analyser provided numerical results from
0 to >200 mg Hb/g faeces, with a manufacturer’s stated
LoD of 2 mg Hb/g faeces and LoQ of 4 mg Hb/g faeces:
10–200 mg Hb/g faeces is conventionally taken as the
working range. Analysis was performed in advance of
colonoscopy in all cases. Feasibility and acceptability
of application of FIT was measured by uptake.
Colonoscopy was performed within 4 weeks of the
FIT test. Patient symptoms were not recorded.
Endoscopists were blind to the f-Hb result and
recorded colonoscopy findings on the hospitals’ elec-
tronic endoscopy reporting systems. Polyp size and
number were verified by a specialist gastrointestinal
pathologist. Adenomatous polyps were grouped
by size (<10 mm, 10 mm) and number. Individuals
with small rectal hyperplastic polyps were
considered as normal. If multiple lesions were present,
classification was based on the most advanced
lesion. HRA was defined as at least three adenoma or
any 10 mm.
Results of f-Hb analysis were correlated with
colonoscopy and pathology findings. Using the
pre-specified analyser and working range thresholds,
sensitivity and specificity of f-Hb for detecting CRC
and HRA were estimated, in addition to positive pre-
dictive values (PPV) and negative predictive values
(NPV), expressed with 95% confidence intervals.
Statistical analyses were performed with MedCalc
(MedCalc Software, Ostend, Belgium).
Results
Altogether, 1103 patients were invited, and 643
returned a FIT device (uptake: 58.3%). Of the 790
patients approached in Dundee, 516 enrolled (64.9%),
compared with 127 of the 313 invited in London
(40.6%). Four patients had IBD and were excluded,
leaving 639 (57.9%) for inclusion. The age range was
25–90 years (median: 64 years, interquartile range
(IQR): 55–71) and 54.6% were male. The indications
for colonoscopy reflected routine surveillance practice
in these hospitals and were: adenoma surveillance in
312 (48.8%), of whom 66.3% were categorised as inter-
mediate risk, 20.5% low risk, 13.2% high risk; genetic
surveillance in 152 (23.8%) (including history of CRC
(89) hereditary nonpolyposis colorectal cancer (19),
familial adenomatous polyposis (16) and mis-match
repair gene carriers (12)),other family history in 84
(13.1%); post-surgical CRC follow-up in 72 (11.3%)
and other indications in 19 (3.0%).
Of the 639 patients, 46 were excluded from analysis
of FIT diagnostic performance; 19 patients did not
respond to the colonoscopy appointment letter or can-
celled their appointment, 8 did not attend, 3 patients
were not fit for colonoscopy, 3 submitted a device that
was unsuitable for analysis, 1 was cancelled, 1 under-
went CT colonoscopy, 2 had an incomplete colonosco-
py and 9 had not undertaken colonoscopy by the end
of the study.
Of the 593 patients who had a f-Hb result and com-
pleted colonoscopy, advanced neoplasia was found in
only 41 (6.9%); (4 CRC (0.7%)), 37 HRA (6.3%)).
Diagnostic performance of FIT
For the detection of 41 cases of advanced neoplasia
within the cohort of 593 patients, the performance of
FIT was assessed at the LoD (2 mg Hb/g faeces)
(Figure 1), LoQ (4 mg Hb/g faeces), and the lower
limit of the usual working range (10 mg Hb/g faeces)
for the assay. With a cut-off threshold for a positive
test at 10 mg Hb/g faeces, 83.3% had a negative test
(Table 1); at this threshold, 3/4 CRC and 17/37 HRA
would have been missed. At the LoD threshold, 59.9%
had a negative test; the yield of pathology at colonos-
copy was doubled at 13.0% (31/238) but 2 of the 4
cancers and 8 of the 37 HRA would have been
missed. Using the LoD as the cut-off for a positive
test result increased the sensitivity for detection of
CRC plus HRA from 51.2% to 75.6%, predominantly
through increased detection of HRA, at the expense of
a reduction in specificity. However, even at the LoD
threshold, the sensitivity for CRC was only 50%; at
this low threshold there was an associated small reduc-
tion in PPV due to the larger number of positive test
results, whilst NPV was unchanged at around 99% due
to the low prevalence of CRC in the study cohort
(Table 2).
The prevalence of advanced neoplasia when grouped
according to the main indications for surveillance was
8.2% in those under adenoma surveillance, 7.2% under
CRC follow up, 6.1% in genetic surveillance, 3.7%
in those with a family history and none of the
five patients under surveillance for other clinical
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indications (Table 3). Assessment of performance of
FIT at the LoD revealed some variation across the sur-
veillance categories. Positivity ranged from 27.5% to
47.8%. The missed CRC were both within the CRC
follow-up cohort, but the numbers in each subgroup
are small, limiting the value of this analysis.
In summary, with the cut-off for a positive FIT
result set at the LoD, almost 60% of surveillance
patients in our study would have had undetectable
f-Hb. An undetectable f-Hb was associated with a
reduction in the overall risk of advanced neoplasia
from 6.9% (in all-comers) to 2.8% (relative risk
Colonoscopy not done
n = 16
Colonoscopy not done
n = 30
1103 invited to return FIT
643 returned FIT (58.3%)
639 eligible
Faecal haemoglobin concentration
< 2 µg Hb/g faeces
n = 371
Faecal haemoglobin concentration
≥2 µg Hb/g faeces
n = 268
Colonoscopy completed
n = 355
Colonoscopy completed
n = 238
CRC/HRA
n = 10
(2.8%)
CRC/HRA
n = 31
(13.0%)
Other/No pathology
n = 345
(97.2%)
Other/No pathology
n = 207
(87.0%)
FIT not returned
n = 460
Excluded
Known IBD = 4
Figure 1. Study flow diagram, depicting the yield of pathology using 2 mg Hb/g faeces (the LoD) as the cut-off for a positive test in a cohort
of patients submitting a FIT test prior to scheduled surveillance colonoscopy.
FIT: faecal immunochemical test; Hb: haemoglobin; LoD: limit of detection.
Table 1. The impact of using FIT cut-offs of LoD, LoQ, and conventional cut-off (<10 mg Hb/g faeces) on percentage of ‘negative’ tests and
the prevalence of missed pathology at those thresholds in a cohort attending surveillance colonoscopy (n ¼ 593) (CRC, HRA, advanced
neoplasia (CRC plus HRA) and LRA).
<2 mg Hb/g faeces (LoD) <4 mg Hb/g faeces (LoQ) <10 mg Hb/g faeces
n % n % n % n %
Colonoscopy diagnosis 593 100 355 59.9 429 72.3 494 83.3
CRC 4 0.7 2 0.6 3 0.7 3 0.6
HRA 37 6.2 8 2.3 9 2.1 17 3.4
CRC plus HRA 41 6.9 10 2.8 12 2.8 20 4.0
LRA 127 21.4 74 20.8 89 20.7 105 21.2
CRC: colorectal cancer; FIT: faecal immunochemical test; Hb: haemoglobin; HRA: higher-risk adenoma; LoD: limit of detection; LoQ, limit of quantitation;
LRA: low-risk adenoma.
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Table 2. Faecal immunochemical test performance at the LoD, LoQ and conventional cut-off (<10 mg Hb/g faeces) for CRC and HRA within
a surveillance cohort (n ¼ 593) expressed as percentages (95% CI).
<2 mg Hb/g faeces (LoD) <4 mg Hb/g faeces (LoQ) <10 mg Hb/g faeces
PPV
CRC 0.8 (0.3–2.2) 0.6 (0.1–3.3) 1.0 (0.2–5.3)
HRA 12.2 (10.2–14.5) 17.1 (14.0–20.6) 20.2 (15.0-26.6)
CRC plus HRA 13.0 (10.9–15.5) 17.7 (14.4–21.5) 21.2 (15.8-27.9)
NPV
CRC 99.4 (98.5–99.8) 99.3 (98.8–99.6) 99.4 (98.9–99.7)
HRA 97.7 (95.9–98.8) 97.9 (96.4–98.8) 96.6 (95.2–97.6)
CRC plus HRA 97.2 (95.3–98.3) 97.2 (95.6–98.3) 96.0 (94.5–97.0)
Sensitivity
CRC 50.0 (6.8–93.2) 25.0 (0.6–80.6) 25.0 (0.6–80.6)
HRA 78.4 (61.8–90.2) 75.7 (58.8–88.2) 54.1 (36.9–70.5)
CRCþHRA 75.6 (59.7–87.6) 70.7 (54.5–83.9) 51.2 (35.1–67.1)
Specificity
CRC 59.9 (55.9–63.9) 72.3 (68.5–75.9) 83.4 (80.1–86.3)
HRA 62.4 (58.2–66.5) 75.5 (71.8–79.1) 85.8 (82.6–88.6)
CRC plus HRA 62.5 (58.3–66.5) 75.5 (71.7–79.1) 85.9 (82.7–88.7)
CI: confidence interval; CRC: colorectal cancer; FIT: faecal immunochemical test; Hb: haemoglobin; HRA: higher-risk adenoma; LoD: limit of detection; LoQ,
limit of quantitation; LRA: low-risk adenoma; NPV: negative predictive value; PPV: positive predictive value.
Table 3. Faecal immunochemical test performance at the LoD (2 mg Hb/g faeces) for each of the four main indications for surveillance
colonoscopy expressed as percentages (95% CI).
Adenoma
Surveillance
(n¼ 292)
Genetics
surveillance
(n¼ 147)
Other family history
(n¼ 80)
CRC
follow up
(n¼ 69)
CRC (n) 1 1 0 2
HRA (n) 23 8 3 3
CRCþHRA (n) 24 9 3 5
FIT test positive at LoD (%) 45.4 33.6 47.8 27.5
Missed pathology
CRC 0 0 0 2
HRA 4 3 1 0
PPV
CRC 0.8 (0.7–0.9) 1.1 (1.0–1.2) N/A 0.0
HRA 14.4 (11.8–17.5) 5.3 (3.1–8.9) 9.1 (4.0–19.5) 9.1 (7.1–11.5)
CRC plus HRA 15.2 (12.4–18.3) 6.4 (4.1–9.9) 9.1 (4.0–19.5) 9.1 (4.5–17.6)
NPV
CRC 100 100 N/A 94.4 (93.1–95.6)
HRA 97.6 (94.3–99.0) 93.6 (85.3–97.4) 98.3 (92.0–99.7) 100
CRC plus HRA 97.6 (94.3–99.0) 93.6 (85.3–97.4) 98.3 (92.0–99.7) 94.4 (85.0–98.1)
Sensitivity
CRC 100 (2.5–100) 100 (2.5–100) N/A 0.0 (0.0–84.2)
HRA 82.6 (61.2–95.1) 62.5 (24.5–91.5) 66.7 (9.4–99.2) 100
CRC plus HRA 83.3 (62.6–95.3) 66.7 (29.9–92.5) 66.7 (9.4–99.2) 60.0 (14.7–94.7)
Specificity
CRC 55.9 (50.0–61.6) 33.6 (25.8–42.0) N/A 50.7 (38.2–63.2)
HRA 58.9 (52.8–64.8) 33.1 (24.5–41.7) 74.0 (62.8–83.4) 54.5 (41.8–66.9)
CRC plus HRA 59.1 (53.1–65.0) 33.1 (25.4–42.1) 74.0 (62.8–83.4) 53.1 (40.2–65.7)
CI: confidence interval; CRC: colorectal cancer; FIT: faecal immunochemical test; Hb: haemoglobin; HRA: higher-risk adenoma; LoD: limit of detection; NPV:
negative predictive value; PPV: positive predictive value.
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reduction of 59.4%), and the risk of CRC from 0.7%
(in all-comers) to 0.6% (relative risk reduction of
14%). On the other hand, a positive FIT was associat-
ed with an increase in prevalence of advanced neoplasia
at colonoscopy from 6.9% (in all comers) to 13.0%.
Discussion
We have studied FIT within the context of colonoscopy
surveillance delivered in two NHS services, one in
Scotland and the other in England. The yield of signif-
icant neoplasia within this surveillance cohort was very
low (6.9%) and CRC accounted for only 0.7%. This is
in keeping with a previously published landmark
study.25 With the cut-off for a positive FIT result set
at the LoD, almost 60% of surveillance patients in our
study had undetectable f-Hb. A positive FIT was asso-
ciated with an increase in prevalence of advanced neo-
plasia at colonoscopy from 6.9% to 13.0%. An
undetectable f-Hb was associated with a reduction in
the overall risk of advanced neoplasia from 6.9% to
2.8% (relative risk reduction of 59.4%) and the risk
of CRC from 0.7% to 0.6% (relative risk reduction
of 14%). However, even at the LoD the sensitivity
for CRC was only 50%.
Completing a FIT prior to surveillance colonoscopy
proved feasible and acceptable to patients. The uptake
in NHS Tayside was close to 70% but was considerably
lower in London; it is not clear why this should be
dissimilar, although the demographic characteristics
of the populations differ considerably, and
population-based bowel screening uptake in Greater
London is similarly low at around 43% as compared
with uptake in NHS Tayside, which was 59.9%, at the
time of this study.26,27
A strength of this study is that the cohort of patients
are representative of routine practice across the UK; a
heterogeneous group at low, moderate and high risk of
CRC and called for colonoscopy in accordance with
the BSG surveillance guidelines. Patients were identi-
fied in date order from endoscopy surveillance regis-
ters, removing selection bias. Most patients under
surveillance had a history of adenoma. This cohort
continually accrues because of participation in the
national bowel screening programmes. Approximately
30% of participants who have positive test results in
the bowel screening programme are found to have an
adenoma,28 and most do accept entry to subsequent
surveillance as a result. Patients under surveillance
because of an underlying genetic risk of CRC were
the second largest group. Under current guidelines,
this group has the shortest surveillance interval of
2 years and therefore makes for the greatest demand
for surveillance colonoscopy. The yield of advanced
neoplasia was 6.5% in this group, which is slightly
higher than the 4.5% reported in a large Danish
study of similar patients.29 Patients with Lynch syn-
drome are at the highest risk of CRC, influenced by
the type of genetic mutation carried, but, despite
aggressive colonoscopy surveillance, interval CRC
still arises, and debate over the most appropriate sur-
veillance interval continues.30
A further strength of this study is that the perfor-
mance characteristics of FIT were examined at low
f-Hb, using the LoD and LoQ as potential cut-offs as
well as the more usual 10 mg Hb/g faeces, as recom-
mended for use in assessment of patients with symp-
toms in the National Institute for Health and Care
Excellence (NICE) diagnostics guidance DG30.31 Our
rationale for this was that the detection of neoplasia
should be the highest possible with current analytical
methodology and technology. As shown in Table 1,
lowering the cut-off from 10 mg Hb/g faeces to the
LoD resulted in more cases of advanced neoplasia
being detected, as expected. The sensitivity for detec-
tion of CRCþHRA increased predominantly through
increased detection of HRA. However, no test is per-
fect; in those patients with an undetectable f-Hb below
the LoD advanced neoplasia was present in 2.8%, of
which CRC accounted for 0,6%. Although this equates
to 50,0% of the CRC being missed, these figures must
be viewed alongside the 0.6% miss rates for CRC at
surveillance colonoscopy.9
A limitation of this study is that the low overall
prevalence of advanced neoplasia makes it difficult to
draw meaningful comparisons of FIT test performance
by indication for surveillance. Others have studied sub-
groups of surveillance patients. Recently, a large study
of patients enrolled in adenoma surveillance who were
offered yearly FIT, and had their scheduled colonosco-
py brought forward from 3 years if FIT was ‘positive’,
reported that 41% of CRC and 67% adenoma would
be missed if colonoscopy was replaced by f-Hb at a cut-
off of 40 mg Hb/g faeces22; data using a cut-off of 10 mg
Hb/g faeces were also considered, and, although a sig-
nificant number of CRC and adenoma would have
been missed, it should be noted that many patients at
the low f-Hb cut-off did not undergo colonoscopy until
2 years after the FIT result. Others have reported that
f-Hb is predictive of yield of advanced neoplasia at
subsequent colonoscopy.32 A recent study from
Australia,33 building on their previous work on the
use of FIT in surveillance,34 found that the risk of
advanced neoplasia following a small adenoma was
lower than that following an advanced adenoma, but
was strongly predicted by a positive FIT result: it was
concluded that reducing frequency of colonoscopy
while providing annual FIT might be a more efficient
use of resources. Recently, these authors suggested
that, rather than omitting any colonoscopy, intervals
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could be lengthened beyond 3 years in a personalised
manner, dependent on f-Hb.35
The findings of our study are therefore of great sig-
nificance. Using FIT in patients presently enrolled in
colonoscopy surveillance programmes could assist
clinicians in determining the underlying risk of
advanced neoplasia and inform patients of the antici-
pated benefits of colonoscopy and associated risks of
declining a colonoscopy. In the future, surveillance of
patients at risk of CRC could take the form of regular
FIT tests, following which patients could be counselled
on their underlying risk of neoplasia based on the FIT
result and individual risk profile, and surveillance colo-
noscopy could be tailored to individual requirements.
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